The report provides detailed analysis essential for establishing a nilutamide production plant. It encompasses all critical aspects necessary for nilutamide production, including the cost of nilutamide production, nilutamide plant cost, nilutamide production costs, and the overall nilutamide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a nilutamide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Nilutamide Market Analysis: Demand and Supply Analysis and Sourcing
Nilutamide is a nonsteroidal antiandrogen medicine used in the treatment of prostate cancer. It works by blocking the action of male hormones, particularly testosterone, which can support the growth of prostate cancer cells. By reducing the effects of these hormones, nilutamide helps slow cancer progression and is used as part of hormone-based treatment, particularly in patients receiving surgical or medical castration. It was originally developed under the code RU-23908 and later marketed under the brand names Nilandron and Anandron.
Nilutamide supply is limited and comes from a small number of manufacturers. One industry directory lists five companies producing the active ingredient in only two countries, India and Argentina. Four manufacturers are based in India and one in Argentina. Among them, one holds a European certificate, and two have United States drug master files. Another directory lists eight suppliers and one written confirmation, showing a difference in the reported supplier numbers. Buyers select suppliers based on regulatory approvals, inspection records, impurity levels, production availability, and minimum order quantities. Supplier records include inspection dates, regulatory filings, batch history, quality issues, staff training, and process changes.
Nilutamide demand is very low and mainly comes from its use in prostate cancer treatment. It is approved for this condition and is used along with a gonadotropin-releasing hormone analog. The usual dose is 300 milligrams per day for the first four weeks, followed by 150 milligrams per day. It is not approved for use alone. Newer medicines have replaced it in many cases, leaving demand limited to specific patients. It remains listed as an alternative treatment in the essential medicines list. Demand depends on treatment guidelines, the availability of alternative medicines, patient tolerance, hospital tenders, and institutional purchases. Tender requirements include tablet strength, pack size, shelf life, delivery time, country registration, and price per tablet.
Summary of the Product, Grades, and Uses
Nilutamide is first classified as a purified active ingredient. Its quality is checked through melting range, active content, and impurity levels. The reported melting point is around 149 degree Celsius. Ethanol is used during the final purification stage, so checks also cover any remaining solvent. Since the production process involves nitroaromatic compounds, color and degradation products are also monitored. Quality tests include active content, impurities, residual solvents, moisture, appearance, and sulfated ash. Release records show the assay result, total impurities, individual unknown impurities, residual ethanol, moisture, and ash content.
Nilutamide is also classified based on its intermediate and impurity standards. The production process forms an imino compound with the formula C12H11F3N4O3, which has a melting point of around 168 degree Celsius. This compound is both an intermediate and an important impurity to monitor. Similar compounds are also prepared as reference materials for laboratory testing. Quality checks focus on identifying individual impurities rather than only measuring their total amount. These include the imino intermediate, unreacted isocyanate, and by-products formed during hydrolysis. Testing also requires reference standards and validated analytical methods. Reference material labels include the chemical formula, melting range, purity, storage conditions, expiry date, and handling instructions.
Nilutamide is also available as finished oral tablets in strengths of 50 milligrams and 150 milligrams. These tablets are sold only on prescription in markets where the medicine is available. The American brand applications covered both strengths, but both products have been discontinued, and a generic version was approved in their place. The original patent described a tablet made with lactose, starch, talc, and magnesium stearate. Finished product quality checks cover tablet appearance, hardness, friability, uniformity of drug content, dissolution, stability, protection from light, and packaging quality. Patient labeling is also checked to ensure that the required information is provided.
Main End-Uses of Nilutamide
Nilutamide is mainly used as part of combined hormone treatment for prostate cancer. It blocks male hormones from binding to androgen receptors, which helps slow cancer growth. It does not block the enzyme 5-alpha reductase. Like other medicines in its class, it can enter the brain and act on both the central nervous system and other parts of the body. Early studies showed that it reduced the growth of the prostate and seminal vesicles in castrated rats. Clinical studies focus on treatment response, hormone blocking, side effects, survival, and the effects of stopping treatment. Patient records track testosterone levels, prostate-specific antigen (PSA), treatment response, bone pain, and overall health.
Nilutamide was also studied for other conditions linked to male hormones. The original patent mentioned its possible use in prostate enlargement and cancer, excessive hair growth, acne, and oily skin. Later studies also examined its use in feminizing hormone therapy and the treatment of acne and oily skin in women. However, these uses did not receive approval and do not account for commercial demand. Research in these areas focuses on suitable doses, skin response, hormone levels, safety, and treatment duration. Studies may also record acne lesions, skin oil production, hair growth, and patient tolerance.
Nilutamide is also used as a reference compound in laboratory studies of antiandrogen medicines. Researchers use it to compare how different compounds bind to androgen receptors and affect their activity. Its relative binding affinity is 0.9 when metribolone is set at 100, compared with 1.4 for bicalutamide and 0.57 for hydroxyflutamide. Unlike bicalutamide, nilutamide can weakly activate the androgen receptor at high concentrations, making it useful for studying receptor activity. Its hydantoin ring structure also served as a basis for developing later antiandrogen compounds. Laboratory studies compare receptor binding, activation levels, cell types, compound concentrations, and testing conditions.
Nilutamide Market Risks
Nilutamide faces major safety concerns that have reduced its use in the market. Interstitial pneumonitis has been reported in 0.77 to 2.4% of patients, with the rate reaching 12.6% in Japanese patients. Severe liver failure, including fatal cases, has also been reported. Mild and reversible vision problems affect 31 to 58% of patients, while around 19% experience an alcohol reaction similar to that caused by disulfiram. These side effects have encouraged doctors to use newer medicines instead. Safety monitoring includes checking lung health, liver function, and vision, along with recording alcohol use and adverse reactions. Medical records include chest scans, liver enzyme results, vision tests, the timing of symptoms, and patient outcomes.
Nilutamide also faces commercial challenges because of its small market size. Its original patent expired several decades ago, and no active United States patent is listed for the molecule. This allows generic competition but offers little protection to manufacturers. Only one finished product supplier is listed for the compound, and its brand has been discontinued in its largest former market. The limited demand makes it difficult for a plant to depend on nilutamide production alone. Commercial risks include low production volumes, minimum order requirements, dependence on hospital tenders, competition from alternative medicines, and the need to share manufacturing facilities with other products. Market assessments consider the number of manufacturers, finished product suppliers, tender volumes, competing product prices, regulatory approvals, and available stock.
Nilutamide Production Process and Main Cost Drivers
Nilutamide is produced in two main stages. First, 2-amino-2-cyanopropane reacts with 3-trifluoromethyl-4-nitrophenyl isocyanate using a suitable base to form an intermediate, which is then treated with acid to produce nilutamide. The process involves mixing, reaction, concentration, separation, hydrolysis, filtration, washing, drying, and milling.
- By Condensation of 2-Amino-2-Cyanopropane with 3-Trifluoromethyl-4-Nitrophenyl Isocyanate over a Tertiary Base in Tetrahydrofuran, Followed by Acid Hydrolysis of the Imino Intermediate to the Hydantoin.
The condensation stage takes the most time in nilutamide production. In the reported process, triethylamine was added to the isocyanate in tetrahydrofuran, followed by 2-amino-2-cyanopropane. The mixture was stirred at 20 degree Celsius for 72 hours and then concentrated under reduced pressure. The intermediate was separated using silica gel chromatography with methylene chloride and acetone. This produced 27 grams of the imino compound, with a melting point of 168 degree Celsius. Process checks include raw material quantities, base amount, moisture, temperature, reaction time, and product weight.
The hydrolysis stage converts the intermediate into nilutamide and helps determine the final product quality. The imino compound was mixed with hydrochloric acid and water, then heated under reflux for one hour. The mixture was cooled, poured into water, filtered, and washed before drying. This produced 9.5 grams of nilutamide with a melting point of 149 degree Celsius. Further crystallization from ethanol gave a purified sample. Quality checks cover acid strength, heating time, cooling, water quantity, filtration, washing, and drying conditions. Batch records also track the amount of material processed and the operating conditions.
Main Factors Affecting Nilutamide Production Cost
The main cost of nilutamide production comes from the isocyanate. It contains both trifluoromethyl and nitro groups, which require several processing stages to produce from basic raw materials. Converting the resulting aniline into an isocyanate adds further cost. The aminonitrile used in the process is much cheaper, while the acid required in the second stage costs even less. Therefore, the yield of the first reaction has a greater effect on production cost than the second. Main raw material expenses include the isocyanate, 2-amino-2-cyanopropane, tertiary base, tetrahydrofuran, hydrochloric acid, and ethanol. Cost calculations consider isocyanate use, aminonitrile quantity, base consumption, solvent use, acid requirements, and processing materials.
Processing costs mainly depend on reaction time and product separation. The first reaction requires around 72 hours of stirring at room temperature, keeping the reactor occupied for three days. This increases production costs because the equipment cannot be used for another batch during this period. Silica gel chromatography is suitable for small laboratory batches but becomes difficult and costly at larger production volumes. Therefore, manufacturers need to develop a crystallization method for product separation. The use of large quantities of tetrahydrofuran also increases solvent recovery costs. Other processing expenses include reactor operating time, solvent recovery, product separation, drying, labor, and quality testing.
Raw Materials for Nilutamide Production Plant and its Procurement
Raw material procurement for nilutamide production starts with the isocyanate. It is purchased based on purity, free amine content, hydrolyzable chloride, color, and moisture levels. The material can react with moisture and form unwanted impurities that may affect the production batch. Finding a reliable supplier of this fluorinated nitroaromatic intermediate is a major challenge because only a few companies manufacture it, and production volumes are limited. Supplier approval involves factory audits, sample testing, stability checks, document reviews and trial batches. Procurement checks also cover purity, moisture, packaging condition, transport requirements and changes in the supplier's production process. Incoming material is tested for purity, water, free amine, chloride content and color, while container seals are also inspected.
Other materials required for nilutamide production include tetrahydrofuran, diethyl ether, isopropyl ether, triethylamine, pyridine, hydrochloric acid, sulfuric acid, methylene chloride, acetone and ethanol. Silica gel is also purchased when chromatography is used for product separation. Tablet manufacturing requires additional ingredients such as lactose, starch, talc and magnesium stearate. Procurement therefore covers solvents, reaction bases, acids, separation materials, tablet ingredients and packaging materials.
Sustainability and Regulatory Requirements
Nilutamide production has environmental concerns mainly due to solvent use and nitroaromatic waste. The process uses large quantities of tetrahydrofuran, along with chlorinated solvents during separation and ethanol during purification. These solvents form the largest waste stream. Nitroaromatic waste requires special treatment and cannot be handled through ordinary biological wastewater treatment. Used silica gel from chromatography also needs to be disposed of as contaminated solid waste. Other waste includes used solvents, acidic wastewater, nitroaromatic residues, and leftover ethanol. Environmental checks cover solvent quantities, chlorinated waste, acid strength, nitroaromatic content, suspended solids, and residues sent for incineration.
Nilutamide is regulated under standard pharmaceutical laws. European supplies require a certificate of suitability, while supplies to the United States are supported by a drug master file. Written confirmation is also required for imports into the European market. Its safety concerns create additional regulatory requirements, particularly for reporting lung and liver-related side effects. Finished nilutamide tablets are available only on prescription. Compliance requirements include good manufacturing practices, impurity testing, stability studies, regular safety reporting, plant inspections, and proper product labeling.
CAPEX and OPEX for a Nilutamide Production Plant
The capital cost of a nilutamide plant is relatively low compared with larger pharmaceutical facilities. However, the production process requires equipment that can handle moisture-sensitive raw materials and long reaction times. The main equipment includes glass-lined or stainless-steel reactors, nitrogen charging systems, condensers, vacuum concentration units, acid-resistant hydrolysis vessels, and quench tanks. Other equipment includes filters, washing units, tray or vacuum dryers, mills and blending units. A crystallizer is also required if chromatography is replaced with crystallization. Tablet manufacturing needs a separate facility. Capital expenses mainly cover reactors, concentrators, hydrolysis vessels, filters, dryers, crystallizers, solvent recovery systems, and wastewater treatment units.
Operating costs mainly depend on isocyanate consumption and the time for which reactors remain occupied. Solvent recovery also affects costs because it determines how much tetrahydrofuran can be reused in each production batch. Quality testing covers active content, impurities, residual solvents, moisture, and heavy metals. Labor costs per kilogram can be high because production batches are limited, while documentation and quality requirements remain fixed. Other operating expenses include equipment maintenance, process qualification, quality control, stability testing, audit requirements, and regulatory activities.
Plant Location and Investment Factors
Nilutamide production depends more on fine chemical manufacturing facilities than on proximity to consumer markets. India has four of the five listed manufacturers, while the remaining producer is based in Argentina. No listed production facilities are reported in China, Europe, or the United States. A suitable plant location needs access to fluorinated intermediates, facilities for handling acids, and systems for recovering solvents. Regulatory approvals and inspection records are also important because manufacturers must meet the requirements of their target markets. Site selection depends on raw material availability, regulatory filings, solvent recovery facilities, wastewater treatment capacity, production scheduling, and transport costs.
Investment in nilutamide production depends on whether existing manufacturing facilities can be shared with other products. Setting up a dedicated plant may not be economical because market demand is too low to keep the production line fully occupied. Since the original patent has expired, new manufacturers can enter the market, but this also creates strong price competition and limits profit margins. The product is more suitable for companies already manufacturing other oncology ingredients that can add nilutamide to their existing production schedule. Investment decisions consider shared equipment, batch size, production frequency, product mix, plant utilization, and expected payback period. Companies also assess capital requirements and the risk of leaving the market if demand declines further.
Major Nilutamide Producing Regions
Nilutamide production is mainly concentrated in India, with one additional manufacturer in South America. Four of the five listed manufacturers are based in India and hold European certification and United States drug master files. Argentina has the only other listed producer. The United States holds the original brand application, which has since been discontinued, along with the first approved generic product manufactured at a specialized facility in Minnesota. France is the place of origin, as the molecule and its production process were developed by a French company during the 1970s. Regional supply depends on regulatory approvals, access to raw materials, inspection records, production capacity, and transportation costs.
Key Nilutamide Producers
Roussel Uclaf
- French originator named as the first assignee on the founding patent.
- Developed the molecule under the code RU-23908 before any brand name.
- Filed the condensation and hydrolysis route that still underlies the chemistry.
- Reports no production figure of its own anywhere reachable.
Sanofi
- Named as the current assignee on the founding patent after corporate succession.
- Carried the brand into European and other markets through its predecessor houses.
- Holds the origin of the molecule rather than the present manufacturing of it.
- Publishes no separate volume for this active ingredient.
ANI Pharmaceuticals
- American house that won the first generic approval for the molecule.
- Makes the product at its own specialist plant in Minnesota.
- Entered through a niche generic strategy rather than a volume one.
- Breaks out no output figure for this product in anything public.
Biophore India Pharmaceuticals
- Indian producer carrying both a European certificate and a United States master file.
- Holds the broadest filing set among the listed makers of this molecule.
- Works the regulated generic channel across several oncology actives.
- Gives no capacity figure anywhere reachable.
Kekule Pharma Limited
- Indian producer holding a United States master file against this molecule.
- Appears on the written confirmation route for European import.
- Runs the compound as one line within a wider oncology active portfolio.
- Leaves its batch scale undisclosed.
Triquim
- Argentine producer and the only listed maker outside India.
- Supplies regional and Latin American demand rather than regulated export markets.
- Carries quality system certification rather than a master file.
- Keeps its output for this product unquantified.